-
Efficacy of varenicline or bupropion and its association with nicotine metabolite ratio among smokers with COPD Respirology (IF 6.9) Pub Date : 2024-03-17 Rui Qin, Zhao Liu, An-qi Cheng, Xin-mei Zhou, Zheng Su, Zi-yang Cui, Jin-xuan Li, Xiao-wen Wei, Liang Zhao, Kian Fan Chung, Dan Xiao, Chen Wang
Nicotine metabolic ratio (NMR) has been associated with nicotine metabolism and smoking characteristics. However, there are few studies on the potential association between NMR and smoking cessation efficacy in smokers with chronic obstructive pulmonary disease (COPD) in China or elsewhere.
-
Effect of off-label targeted drugs on long-term survival in chronic thromboembolic pulmonary hypertension: Insights from a national multicentre prospective registry Respirology (IF 6.9) Pub Date : 2024-03-17 Wanying Xia, Yuling Qian, Yangyi Lin, Ruilin Quan, Yuanhua Yang, Zhenwen Yang, Hongyan Tian, Shengqing Li, Jieyan Shen, Yingqun Ji, Qing Gu, Huijun Han, Changming Xiong, Jianguo He
-
Chronic interstitial lung disease associated with systemic lupus erythematosus: A multicentric study of 89 cases Respirology (IF 6.9) Pub Date : 2024-03-17 Lou Deneuville, Arthur Mageau, Marie Pierre Debray, Karim Sacre, Nathalie Costedoat-Chalumeau, Eric Hachulla, Yurdagul Uzunhan, Erwan Le Tallec, Jacques Cadranel, Sylvain Marchand Adam, David Montani, Martine Rémi-Jardin, Martine Reynaud-Gaubert, Gregoire Prevot, Guillaume Beltramo, Bruno Crestani, Vincent Cottin, Raphael Borie
Chronic interstitial lung disease (ILD) occurs rarely with systemic lupus erythematosus (SLE) as compared with other connective tissue diseases. This multicentric retrospective study of patients with SLE-ILD from the OrphaLung and French SLE networks during 2005–2020 aimed to describe the characteristics of patients with SLE-ILD and analyse factors associated with prognosis.
-
-
Transforming recruitment to clinical trials in COPD Respirology (IF 6.9) Pub Date : 2024-03-18 Tanya Patrick, John R. Hurst
-
-
-
-
-
The impact of hiatus hernia in hypersensitivity pneumonitis Respirology (IF 6.9) Pub Date : 2024-03-13 David A. Heriot, Carmel J. W. Stock, Zain‐Ul‐Abideen Mumtaz, R. Gisli Jenkins, Felix Chua, Phillip L. Molyneaux, Anand Devaraj, Vasilis Kouranos, Athol U. Wells, Elizabetta A. Renzoni, Simon P. G. Padley, Sujal R. Desai, Peter M. George
-
Use of spirometry to detect airflow obstruction Respirology (IF 6.9) Pub Date : 2024-03-04 Chi Chiu Leung
See related article
-
Therapeutic bronchoscopy for malignant central airway obstruction: Introduction to the EpiGETIF registry Respirology (IF 6.9) Pub Date : 2024-03-03 Nicolas Guibert, Pascalin Roy, Lyria Amari, Julien Legodec, Bruno Escarguel, Clément Fournier, Frederic Wallyn, Laurent Cellerin, Christine Lorut, Daniela Usturoi, Thomas Egenod, Nicolas Favrolt, Pascal Schlossmacher, Valerian Bourinet, Perrot Loïc, Samy Lachkar, Juliette Camuset, Amandine Briault, Romain Kessler, Christophe Gut-Gobert, Gilles Mangiapan, Nicolas Carnot, Eric Briens, Adrian Crutu, Armelle
EpiGETIF is a web-based, multicentre clinical database created in 2019 aiming for prospective collection of data regarding therapeutic rigid bronchoscopy (TB) for malignant central airway obstruction (MCAO).
-
Up-to-date data on NightLase laser treatment of snoring for discussion Respirology (IF 6.9) Pub Date : 2024-03-05 Peter R. Dawson
See related Reply
-
Reply: Up-to-date data on NightLase laser treatment of snoring for discussion Respirology (IF 6.9) Pub Date : 2024-03-05 Leba M. Sarkis, Andrew C. Jones, Andrew Ng, Christopher Pantin, Sarah L. Appleton, Stuart G. MacKay
See related Letter
-
Impact of surgical lung biopsy on lung function and survival in patients with idiopathic pulmonary fibrosis in a multi‐centre registry cohort Respirology (IF 6.9) Pub Date : 2024-03-04 Veronica Marcoux, Stacey D. Lok, Prosanta Mondal, Deborah Assayag, Jolene H. Fisher, Shane Shapera, Julie Morisset, Hélène Manganas, Charlene D. Fell, Nathan Hambly, P. Gerard Cox, Martin Kolb, Andrea S. Gershon, Teresa To, Mohsen Sadatsafavi, Nasreen Khalil, Alyson W. Wong, Pearce G. Wilcox, Christopher J. Ryerson, Thao Vu, Kerri A. Johannson
-
The TSANZ and Lung Foundation Australia 2023 landscape survey of lung cancer care across Australia and Aotearoa New Zealand Respirology (IF 6.9) Pub Date : 2024-03-03 Jessica Nash, Tracy Leong, Paul Dawkins, Emily Stone, Henry Marshall, Fraser Brims
-
The long and winding road—Where to now for asthma? Respirology (IF 6.9) Pub Date : 2024-02-29 Christine R. Jenkins, Phillip Bardin
Readers might reasonably ask, why did we choose the title ‘The Future of Asthma’ for this series? This may not seem an obvious question given that we now have a range of treatments that can address the spectrum of asthma severity, along with a suite of self-management, control assessment tools and educational approaches that are necessary adjuncts to available therapies and address the multidimensional
-
Recommendations from The Medical Education Editor Respirology (IF 6.9) Pub Date : 2024-02-27 Mark Lavercombe
It is a privilege to highlight several articles published in Respirology of continuing educational value, and the following three papers were selected for this quarterly editorial: Bianquis C, Rolland-Debord C, Rivals I, Similowski T, Morélot-Panzini C. Dyspnoea relief as an inherent benefit of high flow nasal cannula therapy: a laboratory randomized trial in healthy humans. https://onlinelibrary.wiley
-
Chronic cough: New guidelines, new approaches and new treatments Respirology (IF 6.9) Pub Date : 2024-02-27 Richard Turner, Stuart Mazzone, Surinder Birring
The end of 2023 brought with it updated national clinical statements on the management on chronic cough from both Australia and the United Kingdom.1, 2 Both were long in coming, being published 13 and 17 years since their predecessor documents, respectively. Much has changed in the intervening time in the understanding of cough, necessitating and informing the statement updates. Chronic cough in adults
-
Smoking, respiratory symptoms, lung function and life expectancy: A longitudinal study of ageing Respirology (IF 6.9) Pub Date : 2024-02-26 Kate Petrie, Michael J. Abramson, Johnson George
Background and ObjectivePrognostic indices have been developed to predict various outcomes, including mortality. These indices and hazard ratios may be difficult for patients to understand. We investigated the association between smoking, respiratory symptoms and lung function with remaining life expectancy (LE) in older adults.MethodsData were from the 2004/05 English Longitudinal Study of Ageing
-
Using change in 6‐minute walk distance to predict survival in progressive pulmonary fibrosis: A promising measure in need of precision Respirology (IF 6.9) Pub Date : 2024-02-26 Anne E. Holland, Leona Dowman
See related article
-
Enhancing exercise tolerance in interstitial lung disease with high-flow nasal cannula oxygen therapy: A randomized crossover trial Respirology (IF 6.9) Pub Date : 2024-02-22 Yorihide Yanagita, Shinichi Arizono, Koshi Yokomura, Kumiko Ito, Hikaru Machiguchi, Yuichi Tawara, Norimasa Katagiri, Yuki Iida, Eiji Nakatani, Takako Tanaka, Ryo Kozu
-
Oxygen therapy could improve survival in patients with early desaturation in the 6-minute walk test: A post hoc analysis Respirology (IF 6.9) Pub Date : 2024-02-25 Ignacio García-Talavera, Juan Marco Figueira-Gonçalves, Cristobal Esteban, Rafael Golpe, Silvia García-Talavera, Carlos Amado, Amaia Aramburu, Lina I. Pérez-Méndez, Alicia Conde-Martel
Long-term domiciliary oxygen therapy (LTDOT) in patients with chronic obstructive pulmonary disease (COPD) has been shown to increase survival when associated with severe hypoxaemia at rest,1, 2 but not when accompanied by moderate hypoxaemia at rest.3, 4 However, the benefits of LTDOT in patients with COPD and moderate hypoxaemia at rest and with desaturation during exercise are unknown, although
-
What makes asthma characterized by airway eosinophilia become severe? Respirology (IF 6.9) Pub Date : 2024-02-25 Thomas Rothe, Niki Ubags, Christophe von Garnier
Eosinophilic type-2 inflammation is a feature of both allergic early-onset asthma (AEOA) and eosinophilic adult-onset asthma (EAOA). Normally, inhaled corticosteroids (ICS) provide a successful clinical response at moderate dosing, but patients with severe asthma may require high-dose ICS and sometimes even daily oral corticosteroids (OCS) to achieve asthma control. However, despite optimized inhaled
-
Changing trends in mesothelioma: Important lessons for an occupational disease registry Respirology (IF 6.9) Pub Date : 2024-02-25 Hayley Barnes, Ryan F. Hoy
See related article
-
Let's talk about obesity in respiratory disease Respirology (IF 6.9) Pub Date : 2024-02-23 Vanessa Marie McDonald
Obesity is a chronic and relapsing condition where weight loss is often associated with regain of weight over time.1 The prevalence of obesity is increasing, and it is now referred to as a global pandemic.2 Prevalence data suggest that by 2035, over 4 billion people worldwide may be living with overweight (BMI ≥25 kg/m2) or obesity, compared with the 2020 prevalence of 2.6 billion.3 The prevalence
-
Local knowledge: Every surfer knows the feeling Respirology (IF 6.9) Pub Date : 2024-02-20 Peter Gerard Gibson
Why is it so hard for our patients to receive the proven benefits of therapies and management approaches? You would think it should be an easy road from a positive randomized controlled trial to implementation of an effective treatment approach. But this gap between what we know works and what we actually do, ‘the know-do gap’, is large and cavernous. There is a key element, that is seldom recognized
-
Combined effect of changes in NO2, O3, PM2.5, SO2 and CO concentrations on small airway dysfunction Respirology (IF 6.9) Pub Date : 2024-02-20 Hyun Woo Lee, Hyo Jin Lee, Sohee Oh, Jung-Kyu Lee, Eun Young Heo, Deog Kyeom Kim
-
Asthma in children—What's in the future Respirology (IF 6.9) Pub Date : 2024-02-21 Peter Neils Le Souëf
Key points Asthma treatment has been largely unchanged for 50 years. New mechanistic studies promise to lead to the next major advances. Immunomodulation to enhance interferon responses shows great promise. Climate change affects asthma already and is going to get worse. Advances in asthma therapy are long overdue, as little has changed since inhaled corticosteroids were introduced 50 years ago. Biologics
-
Diabetes and lung function: Linked, but how? Respirology (IF 6.9) Pub Date : 2024-02-21 Alan James
See related article
-
-
Next-generation sequencing using tissue specimen collected with a 1.1 mm-diameter cryoprobe in patients with lung cancer Respirology (IF 6.9) Pub Date : 2024-02-20 Mi-Hyun Kim, Soo Han Kim, Geewon Lee, Jeongha Mok, Min Ki Lee, Ju Sun Song, Jung Seop Eom
-
Siloed thinking is limiting health care delivery Respirology (IF 6.9) Pub Date : 2024-02-20 Paul N. Reynolds
The cost of healthcare is an ever-present challenge in all health systems globally. Those of us living in developed countries face this problem in our day-to-day work much less frequently than those in developing economies, but every so often situations emerge that remind us of the realities of limited resources. This is especially the case when new therapies come onto the market, with the need to
-
Lung ultrasound is a promising screening tool to rule out interstitial lung disease in patients with rheumatoid arthritis Respirology (IF 6.9) Pub Date : 2024-02-19 M. Otaola, F. Paulin, M. Rosemffet, J. Balcazar, M. Perandones, P. Orausclio, T. Cazenave, S. Rossi, S. Marciano, E. Schneeberger, G. Citera
-
Low bleeding rates following transbronchial lung cryobiopsy in unclassifiable interstitial lung disease Respirology (IF 6.9) Pub Date : 2024-02-14 John Taverner, Carmen M. Lucena, Justin L. Garner, Christopher M. Orton, Andrew G. Nicholson, Sujal R. Desai, Athol U. Wells, Pallav L. Shah
Bronchoscopic transbronchial lung cryobiopsy (TBLC) is a guideline-endorsed alternative to surgical lung biopsy for tissue diagnosis in unclassifiable interstitial lung disease (ILD). The reported incidence of post-procedural bleeding has varied widely. We aimed to characterize the incidence, severity and risk factors for clinically significant bleeding following TBLC using an expert-consensus airway
-
Respiratory health effects of cannabis—How should we respond to liberalization of cannabis laws? Respirology (IF 6.9) Pub Date : 2024-02-12 Robert J. Hancox
Key points Liberalization of cannabis laws is likely to lead to increasing use among some people. Cannabis is a potent cause of symptomatic bronchitis. Quitting it improves symptoms. Some heavy cannabis users develop severe bullous lung disease. Although cannabis changes lung function, the effects appear different to tobacco and there is insufficient evidence that this causes emphysema or chronic obstructive
-
Similarities and differences of interstitial lung disease associated with pathogenic variants in SFTPC and ABCA3 in adults Respirology (IF 6.9) Pub Date : 2024-02-12 Rémi Diesler, Marie Legendre, Salim Si-Mohamed, Pierre-Yves Brillet, Lidwine Wemeau, Effrosyni D. Manali, Frédéric Gagnadoux, Sandrine Hirschi, Gwenaël Lorillon, Martine Reynaud-Gaubert, Vanessa Bironneau, Elodie Blanchard, Arnaud Bourdin, Stéphane Dominique, Aurélien Justet, Julie Macey, Sylvain Marchand-Adam, Hélène Morisse-Pradier, Hilario Nunes, Spyros A. Papiris, Julie Traclet, Ibrahim Traore
-
Blowing in the wind—Tobacco control legislation Respirology (IF 6.9) Pub Date : 2024-02-08 Natasha Smallwood
As I was contemplating what to write about for this reflection, I was tempted to highlight the increasing tendency to incorporate song titles or lyrics into the titles of articles in respiratory medicine journals. This can be a creative way to engage readers' attention while conveying the essence of the research. And this year, we have had some rather amusing attempts to capture the imagination, with
-
Cone-beam CT imaging for robotic navigation bronchoscopy Respirology (IF 6.9) Pub Date : 2024-02-07 David Fielding, Erik H. F. M. van der Heijden
See related article
-
Use of 6-minute walk distance to predict lung transplant-free survival in fibrosing non-IPF interstitial lung diseases Respirology (IF 6.9) Pub Date : 2024-02-06 Umberto Zanini, Fabrizio Luppi, Karina Kaur, Niccolò Anzani, Giovanni Franco, Giovanni Ferrara, Meena Kalluri, Marco Mura
The identification of progression in patients with fibrosing non-idiopathic pulmonary fibrosis (IPF) interstitial lung diseases (ILDs) represents an ongoing clinical challenge. Lung function decline alone may have significant limitations in the detection of clinically significant progression. We hypothesized that longitudinal changes of 6-min walk distance (6MWD) from baseline, simultaneously considered
-
Breaking the spiral: How negative mood can fuel exertional breathlessness in people with chronic obstructive pulmonary disease Respirology (IF 6.9) Pub Date : 2024-02-01 Amy Pascoe, Natasha Smallwood
See related article
-
C-reactive protein as a candidate biomarker in fibrotic interstitial lung disease Respirology (IF 6.9) Pub Date : 2024-01-31 Vincent Cottin, Claudia Valenzuela
See related article
-
Increased exacerbations of bronchiectasis following recovery from mild COVID-19 in patients with non-cystic fibrosis bronchiectasis Respirology (IF 6.9) Pub Date : 2024-01-30 Wang Chun Kwok, James Chung Man Ho, Terence Chi Chun Tam, Mary Sau Man Ip, David Chi Leung Lam
-
Letter from the UK: Reflections on a turbulent 5 years Respirology (IF 6.9) Pub Date : 2024-01-23 Stephen T. Holgate
Almost 5 years ago, in my ‘letter from the UK’, I expressed concerns about BREXIT. What has happened since its declaration 1 year later has hardly been a success story either economically or in respect of the UK's contributions to health and science. After several years of toing and froing, on 4 December 2023, the EU and UK completed the final step towards association to Horizon Europe. At the same
-
Comparison of the specimen quality of endobronchial ultrasound-guided intranodal forceps biopsy using standard-sized forceps versus mini forceps for lung cancer: A prospective study Respirology (IF 6.9) Pub Date : 2024-01-21 Toshiyuki Nakai, Yuji Matsumoto, Takahiro Ueda, Yuko Kuwae, Sayaka Tanaka, Atsushi Miyamoto, Yoshiya Matsumoto, Kenji Sawa, Kanako Sato, Kazuhiro Yamada, Tetsuya Watanabe, Kazuhisa Asai, Hideaki Furuse, Keigo Uchimura, Tatsuya Imabayashi, Riki Uenishi, Mitsuru Fukui, Hidenori Tanaka, Masahiko Ohsawa, Tomoya Kawaguchi, Takaaki Tsuchida
-
-
Our journey to the 27th APSR Congress 2023 Respirology (IF 6.9) Pub Date : 2024-01-18 Albert Yick-Hou Lim, Jeffrey Shuen-Kai Ng
Singapore Thoracic Society (STS) was founded by Dr Chew Chin Hin in 1974. It aims to promote advancement, research and education in Respiratory Medicine by organizing publications and global collaborations. During the 1980s–1990s, STS hosted World Conference on Tuberculosis and Respiratory Disease and 3rd Congress of Asian Pacific Society of Respirology (APSR). By 2000s, STS faced challenges of staying
-
Lung function changes in children exposed to mine fire smoke in infancy Respirology (IF 6.9) Pub Date : 2024-01-14 Emily J. Hemstock, Rachel E. Foong, Graham L. Hall, Amanda J. Wheeler, Shyamali C. Dharmage, Marita Dalton, Grant J. Williamson, Caroline Gao, Michael J. Abramson, Fay H. Johnston, Graeme R. Zosky
-
Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision Respirology (IF 6.9) Pub Date : 2024-01-11 John A. Mackintosh, Gregory Keir, Lauren K. Troy, Anne E. Holland, Christopher Grainge, Daniel C. Chambers, Debra Sandford, Helen E. Jo, Ian Glaspole, Margaret Wilsher, Nicole S. L. Goh, Paul N. Reynolds, Sally Chapman, Steven E. Mutsaers, Sally de Boer, Susanne Webster, Yuben Moodley, Tamera J. Corte
Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti-fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New
-
Trajectory of lung function in diabetic adults: A 16-year follow-up study of community-based prospective cohorts Respirology (IF 6.9) Pub Date : 2024-01-07 Wonsuk Choi, Joon Ho Moon, Hayoung Choi, Hyun Lee, Hee Kyung Kim, Ho-Cheol Kang, Nam H. Cho
To investigate the difference in lung function according to diabetes status in a community-based prospective study.
-
Letter from Australia Respirology (IF 6.9) Pub Date : 2024-01-04 Christine F. McDonald
Over the last few years many of the ‘Letters from Asia-Pacific and Beyond’ published in this journal have reflected on COVID-19 in its various forms, including how national responses to the pandemic have varied. The timing of my writing this letter from Australia finds me with a ‘scratchy’ throat. Last year, this would have been the harbinger of my first bout of COVID, whereas this year it's related
-
The Western Australian Mesothelioma Registry: Analysis of 60 years of cases Respirology (IF 6.9) Pub Date : 2023-12-28 Fraser Brims, Chellan Kumarasamy, Lalitha Menon, Nola Olsen, Nick de Klerk, Peter Franklin
-
Mild asthma: Conundrums, complexities and the need to customize care Respirology (IF 6.9) Pub Date : 2023-12-25 Christine R. Jenkins
Mild and moderate asthma cover a wide range of asthma presentations, phenotypes and symptom burden, and account for the majority of people with asthma worldwide. Mild asthma has been difficult to define because of its heterogeneity and wide spectrum of impact and outcomes, including being associated with severe exacerbations. Assessment of mild–moderate asthma is best made by combining asthma symptom
-
Systematic mediastinal staging in non-small cell lung cancer: Filling in the guideline evidence gap Respirology (IF 6.9) Pub Date : 2023-12-25 Daniel P. Steinfort
See related article
-
The raw stuff we cannot do without Respirology (IF 6.9) Pub Date : 2023-12-22 Philip Bardin
This month's column is being typed ‘par ordinateur’; that is on a computer. Computers use three of six raw materials that are going to be in short supply in the not too distant future: quartz, copper and lithium. How come? It is not something we think much about, but it will affect us all—scientists, health care professionals, respiratory physicians. This edition's column reflects insights provided
-
Education, education, education! Respirology (IF 6.9) Pub Date : 2023-12-22 Elisabetta Renzoni, Steve Jones
Illness is frightening. Although Buddhist philosophy teaches us that change is an intrinsic part of life, we expect our bodies and minds to continue to function as they always have. When symptoms appear or we are told a test has unexpectedly thrown up a serious issue, it is difficult to adjust to the new reality and find the strength to deal with it. Education about what is wrong will not completely
-
The low hanging fruit of anti-inflammatory reliever therapy Respirology (IF 6.9) Pub Date : 2023-12-22 Richard Beasley
The Global Initiaitive for Asthma (GINA) strategy recommendation that ICS (inhaled corticosteroid)/formoterol is preferred to short-acting beta-agonists as reliever therapy, across the range of asthma severity, in adolescents and adults, possibly represents the greatest paradigm change in the management of asthma for decades. As might be expected for such a marked change in practice, this recommendation
-
-
Respirology and family medicine Respirology (IF 6.9) Pub Date : 2023-12-20 David Chi-Leung Lam
Last month, I got invited to speak at the 7th Oriental Congress of Respiratory Medicine in Shanghai. I was deeply impressed by the joint effort made by Respiratory physicians to host a concurrent conference in family medicine. The Congress program showcased an appropriate mix of topics that are of common interest to both respiratory and family physicians, with accommodation of important topics like
-
Clinical course of suspected familial and sporadic idiopathic pulmonary fibrosis: Data from the PROOF-Next registry Respirology (IF 6.9) Pub Date : 2023-12-20 Antoine Froidure, Benjamin Bondue, Caroline Dahlqvist, Julien Guiot, Natacha Gusbin, Gil Wirtz, Guy Brusselle, Danielle Strens, Hans Slabbynck, Wim A. Wuyts
Real-life data on suspected familial fibrosis, defined as the occurrence of the disease in a patient younger than 50 and/or having at least one relative affected by pulmonary fibrosis remain scarce.